Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
Summary Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the Nasdaq Exchange at a pre-money equity value of $834 million. Simcere Pharma of Nanjing announced a $507 million out-licensing to Spain’s Almirall for ex-China rights to ...
Almirall, S.A. (LBTSF) Q2 2022 Results Earnings Conference Call July 25, 2022, 04:00 AM ET Company Participants Pablo Divasson del Fraile - Director of Investor Relations, Shareholders and ESG Gianfranco Nazzi - Chief Executive Officer Karl Ziegelbauer - Executiv...
The following slide deck was published by Almirall, S.A. in conjunction with their 2022 Q2 earnings call. For further details see: Almirall, S.A. 2022 Q2 - Results - Earnings Call Presentation
Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1 PR Newswire Strong operational performance during the first half of the year. The business continues to perform well boosted by the growth in Core Net Sales (+5.1% year-on-year) from key products...
Evotec (OTCPK:EVOTF) (NASDAQ:EVO) and Almirall (OTC:LBTSF) are collaborating to discover therapies for severe skin diseases. Under the agreement, Evotec will get an undisclosed upfront payment, research payments, and success-based milestones of potentially up to €230M per program and r...
Almirall, S.A. (LBTSF) Q1 2022 Earnings Conference Call May 9 2022 4:00 AM ET Company Participants Carlos Gallardo Piqué - Chairman and President Gianfranco Nazzi - Chief Executive Officer Mike McClellan - Chief Financial Officer Karl Ziegelbauer - Chief Scientific Officer Pablo Divasson...
Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance PR Newswire BARCELONA, Spain , May 9, 2022 /PRNewswire/ -- Good start to the year with Core Net Sales* at €218.8 MM (+1.6% year-on-year) driven by recently lau...
Almirall, S.A. press release (OTC:LBTSF): FY Normalised Net Income was €81.4M. Revenue of €836.5M (+2.7% Y/Y). Core Net Sales reached €809.8M, a 7.2% year-on-year increase. Core EBITDA of €211.3 MM (+17% Y/Y). 2022 Full Year Guidance: ...
Almirall, S.A. (LBTSF) Q4 2021 Earnings Conference Call February 21, 2022 4:00 AM ET Company Participants Pablo Divasson - Head of Investor Relations Gianfranco Nazzi - Chief Executive Officer Karl Ziegelbauer - Chief Scientific Officer Mike McClellan - Chief Financial Officer Conference Call...
The following slide deck was published by Almirall, S.A. in conjunction with their 2021 Q4 earnings call. For further details see: Almirall, S.A. 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...
Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing. ...
Positive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines, with Ilumetri ® showing 30% increase in sales vs Q1 ...